KALV News and Press, KalVista Pharmaceuticals Inc. From 06/02/23

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced the acceptance of multiple abstracts at the 2023 European Academy of Allergy and Clinica...

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced it will present at the Jefferies Global Healthcare Conference on Wednesday, June 7th, 20...

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced it will participate in a fireside chat at the Stifel 2023 Tailoring Genes: Genetic Medic...

– Phase 1 data provide rationale for sebetralstat as short-term prophylaxis for medical and dental procedures - – Patient survey data demonstrate treatment burden associated with injectable on-demand treatments for HAE - KalVista Pharmaceuticals, Inc. (NASDAQ: KA...

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced the acceptance of multiple abstracts at the 13th C1-inhibitor Deficiency & Angioedem...

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced it will participate in a fireside chat at the 22 nd Annual Needham Virtual Healthcar...

2023-03-29 17:30:23 ET Gainers: Erasca ( ERAS ) +8% . KalVista Pharmaceuticals ( KALV ) +5% . Ramaco Resources ( METC ) +5% . Pyxis Oncology ( PYXS ) +5% . Yellow Corporation ( YELL ) +5% . Losers: Semtech  ( SMTC ...

2023-03-09 07:17:48 ET KalVista Pharmaceticals press release ( NASDAQ: KALV ): Q3 GAAP EPS of -$0.75 beats by $0.26 . Cash, cash equivalents and marketable securities were $171.7 million as of January 31, 2023, compared to $166.2 million as of April 30, 2022. For...

– Orally disintegrating tablet formulation shows similar pharmacokinetics to current film-coated tablets supporting lifecycle extension in US and EU - – Real-word evidence and patient survey data demonstrate treatment burden associated with the administration of injectable...

Summary BioCryst's main value driver, ORLADEYO, is already profitable in its second year on the market and generated over $250 million in revenue in 2022. ORLADEYO is successfully differentiating itself in a multi-billion dollar market and is on track to achieve blockbuster status in a ...